Insider Selling: Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $55,000.00 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Patrick R. O’neil sold 1,000 shares of the business’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $55.00, for a total value of $55,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ionis Pharmaceuticals, Inc. (IONS) opened at 55.55 on Monday. The stock has a 50 day moving average price of $53.28 and a 200-day moving average price of $48.97. The company has a market cap of $6.91 billion, a price-to-earnings ratio of 267.07 and a beta of 3.12. Ionis Pharmaceuticals, Inc. has a 1-year low of $24.58 and a 1-year high of $60.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The business had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. During the same quarter in the prior year, the firm earned ($0.47) EPS. Ionis Pharmaceuticals’s revenue for the quarter was up 170.7% on a year-over-year basis. On average, equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.17) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $55,000.00 in Stock” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/10/09/insider-selling-ionis-pharmaceuticals-inc-ions-svp-sells-55000-00-in-stock.html.

Institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC increased its stake in shares of Ionis Pharmaceuticals by 62.8% in the 2nd quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock valued at $109,000 after purchasing an additional 800 shares in the last quarter. Westpac Banking Corp acquired a new stake in Ionis Pharmaceuticals in the 1st quarter worth about $171,000. Hanseatic Management Services Inc. boosted its holdings in Ionis Pharmaceuticals by 1.2% in the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after buying an additional 41 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after buying an additional 311 shares during the last quarter. Finally, WFG Advisors LP boosted its holdings in Ionis Pharmaceuticals by 77.2% in the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after buying an additional 1,655 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

IONS has been the subject of several recent analyst reports. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a research note on Monday, July 31st. Needham & Company LLC restated a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Laidlaw restated a “buy” rating and issued a $65.00 price target on shares of Ionis Pharmaceuticals in a research note on Monday, August 14th. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. Finally, Barclays PLC initiated coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price target for the company. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $49.44.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

<

Ionis Pharmaceuticals, Inc. (IONS) opened at 55.55 on Monday. The stock has a 50 day moving average price of $53.28 and a 200-day moving average price of $48.97. The company has a market cap of $6.91 billion, a price-to-earnings ratio of 267.07 and a beta of 3.12. Ionis Pharmaceuticals, Inc. has a 1-year low of $24.58 and a 1-year high of $60.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The business had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. During the same quarter in the prior year, the firm earned ($0.47) EPS. Ionis Pharmaceuticals’s revenue for the quarter was up 170.7% on a year-over-year basis. On average, equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.17) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $55,000.00 in Stock” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/10/09/insider-selling-ionis-pharmaceuticals-inc-ions-svp-sells-55000-00-in-stock.html.

Institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC increased its stake in shares of Ionis Pharmaceuticals by 62.8% in the 2nd quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock valued at $109,000 after purchasing an additional 800 shares in the last quarter. Westpac Banking Corp acquired a new stake in Ionis Pharmaceuticals in the 1st quarter worth about $171,000. Hanseatic Management Services Inc. boosted its holdings in Ionis Pharmaceuticals by 1.2% in the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after buying an additional 41 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after buying an additional 311 shares during the last quarter. Finally, WFG Advisors LP boosted its holdings in Ionis Pharmaceuticals by 77.2% in the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after buying an additional 1,655 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

IONS has been the subject of several recent analyst reports. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a research note on Monday, July 31st. Needham & Company LLC restated a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Laidlaw restated a “buy” rating and issued a $65.00 price target on shares of Ionis Pharmaceuticals in a research note on Monday, August 14th. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. Finally, Barclays PLC initiated coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price target for the company. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $49.44.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply